Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
As of today, Intellia Therapeutics(NTLA) shares are valued at $12.01. The company's market cap stands at 1.89B, with a P/E ratio of -3.58.
During the trading session on 2026-08-12, Intellia Therapeutics(NTLA) shares reached a daily high of $12.31 and a low of $11.88. At a current price of $12.01, the stock is +1.1% higher than the low and still -2.4% under the high.
Trading activity shows a volume of 2.04M, compared to an average daily volume of 3.66M.
The stock's 52-week range extends from a low of $7.95 to a high of $28.25.
The stock's 52-week range extends from a low of $7.95 to a high of $28.25.
NTLA News
Intellia Therapeutics (NTLA) reported Q2 2026 results that kept the company in loss making territory, although the net loss and loss per share for both the quar...
Analysts are intrested in these 5 stocks: ( (NTLA) ) and ( (ROKU) ). Here is a breakdown of their recent ratings and the rationale behind them. Claim 55% Off Ti...
Whitney Ijem, an analyst from Canaccord Genuity, maintained the Buy rating on Intellia Therapeutics. The associated price target remains the same with $49.00. C...
Analyst ratings
53%
of 19 ratingsMore NTLA News
As previously reported, Evercore ISI analyst Jonathan Miller upgraded Intellia Therapeutics (NTLA) to Outperform from In Line with a price target of $24, up fro...
Intellia Therapeutics stock is coming off a very heavy five year decline, yet the current valuation checks still suggest a mixed picture rather than a clear bar...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.